

Transcriptomic and Functional Approaches Unveil the Role of tmRNA in Zinc Acetate Mediated Levofloxacin Sensitivity in *Helicobacter Pylori*

Hongjin Tao

Department of Gastroenterology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.

Fansen Meng

Department of Gastroenterology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.

Yu Zhou

Department of Laboratory Medicine, Second Medical Center, Chinese PLA General Hospital, Beijing, China.

Jiao Fan

Institute of Geriatrics, National Clinical Research Center of Geriatrics Disease, Second Medical Center, Chinese PLA General Hospital, Beijing, China.

Jing Liu

Institute of Geriatrics, National Clinical Research Center of Geriatrics Disease, Second Medical Center, Chinese PLA General Hospital, Beijing, China.

Yingjie Han

Department of Oncology, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.

Benjamin B. Sun

MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.

Gangshi Wang (✉ wanggangshi@hotmail.com)

Department of Gastroenterology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.

Research Article

Keywords: *Helicobacter pylori*, zinc acetate, levofloxacin resistance, transcriptomics, ssrA

Posted Date: February 8th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1331647/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Rapid increase in resistance of *Helicobacter pylori* (*H. pylori*) has hindered antibiotics-based eradication efforts worldwide and raises the need for additional approaches. Here, we investigate the role of zinc-based compounds in inhibiting *H. pylori* growth and modulating antibiotic sensitivities, interrogate their downstream transcriptomic changes and highlight the potential mechanism driving the observed effects.

Results: We showed that zinc acetate inhibited *H. pylori* growth and increased *H. pylori* sensitivity to levofloxacin. Transcriptomic profiling showed distinct gene expression patterns between zinc acetate treated groups vs controls. In particular, we independently replicated the association between zinc acetate treatment and increased *ssrA* expression. Knockdown of *ssrA* restored levofloxacin resistance to levels of the control group.

Conclusion: In this study, we first demonstrated the role of zinc acetate in *H. pylori* growth and antibiotic sensitivities. Additionally, we explored the transcriptomic perturbations of zinc acetate followed by functional knockdown follow-up of differentially expressed *ssrA*, highlighting the role of tmRNA and trans-translation in *H. pylori* levofloxacin resistance. Our results provide alternative and complementary strategies for *H. pylori* treatment and shed light on the underlying mechanisms driving these effects.

Background

Helicobacter pylori (*H. pylori*) infection is one of the leading causes of chronic gastric inflammation, predisposing individuals to peptic ulcerations and gastric cancer [1-3]. Approximately more than half of the worldwide population carry *H. pylori* within the gastric mucosa with prevalence in certain regions such as Asia exceeding 80% [4, 5]. Eradication of *H. pylori* reduces the long-term risks of peptic ulcers and gastric cancer [6, 7] and is fast becoming an emerging global health issue [8].

Current first-line treatment for *H. pylori* in general consists of a proton pump inhibitor with a combination of three or four antibiotics, such as penicillin-based or fluoroquinolones combined with macrolides and metronidazole, depending on local resistance patterns [9, 10]. The combination of antibiotic treatment reflects the challenges in *H. pylori* eradication [11], and rapidly increasing resistance to current antibiotic therapies [12] is a particular cause for concern. Therefore, additional means to inhibit *H. pylori* growth and increase their sensitivity to existing antibiotics are needed to tackle this increasingly difficult to treat endemic.

Various alternate treatment approaches have been investigated previously (reviewed in detail in [13]), however, many showed limited efficacy. Metal complexes, such as bismuth are commonly added to *H. pylori* combination therapies in wide-spread clinical settings [14]. Zinc-based complexes in particular, such as the addition of polaprezinc (a chelate compound of zinc and L-carnosine) to combination therapies, have been shown to improve *H. pylori* eradication [15, 16]. Currently, there have been limited studies examining effects of zinc acetate on *H. pylori* growth and sensitivities to antibiotics.

Here we demonstrate (1) the inhibitory effect of zinc acetate on *H. pylori* growth *in vitro*, (2) explore the transcriptomic changes in response to zinc acetate, and (3) investigate the knockdown effects of the differentially expressed transfer-messenger RNA (*ssrA*) on antibiotic sensitivity.

Methods

Bacteria strains and culture conditions

H. pylori NCTC 11637, Sydney strain 1 (SS1) and clinical strains used in this study have been identified using 16S rDNA sequencing. *H. pylori* strains were cultured under microaerophilic condition (5% O₂, 10% CO₂ and 85% N₂) on solid culture media which composed of Karmali Agar Base (CM0935, Oxoid, UK) and 5% sterile defibrinated sheep blood (XLF Medical Sales Co., Beijing, China).

Bacteria growth at different concentrations of zinc compounds

Culture mediums containing different concentrations of zinc acetate or polaprezinc were prepared. *H. pylori* NCTC 11637 was resuspended to 10⁵ cfu/ml and 100 µl of bacteria suspension was evenly coated on culture medium and colonies were counted after incubating at 37 °C for 3 days.

Minimal inhibitory concentrations (MICs) of zinc compounds to *H. pylori*

H. pylori strains - two standard strains (NCTC 11637 and SS1) and eight clinical strains (19004, 20050, 27054, 28038, 827, L1, L2, L3) - were resuspended in sterile PBS to 2 McFarland. 100 µl bacteria suspension was evenly coated on culture medium with 0.0005 mmol/ml, 0.001 mmol/ml, 0.0025 mmol/ml, 0.005 mmol/ml, 0.01 mmol/ml of zinc compounds. After incubating at 37 °C for 3 days, concentration of the zinc compounds in the plate with no bacterial grow was regarded as MIC.

Zinc compound effects on MICs of antibiotics to *H. pylori*

H. pylori NCTC 11637 strain was used. Culture mediums containing half MIC of zinc compounds (0.0005 mmol/ml for polaprezinc and 0.00125 mmol/ml for zinc acetate) were prepared. *In vitro* MICs of three antibiotics: levofloxacin, clarithromycin and tetracycline were tested using the Epsilon test (E-test, Liofilchem, Italy). The MIC value was read at the point where the bacteriostatic ring intersects the E-test strip. The clinical breakpoints for levofloxacin, clarithromycin and tetracycline were defined as: >1 µg/ml, >0.5 µg/ml, and >1 µg/ml, respectively as per European Committee on Antimicrobial Susceptibility Testing Breakpoints [17].

Genome DNA extraction and analyses

H. pylori NCTC 11637 was divided into two groups. The experimental group was incubated on medium contains 0.00125 mmol/ml zinc acetate for 3 days and the control group was incubated on blank medium for 3 days. DNA was extracted using sodium dodecyl sulphate (SDS) method [18]. Qubit RNA Assay Kit in Qubit 2.0 Fluorometer (Life Technologies, USA) was used to quantify the extracted DNA, and

its purity and integrity was determined by agarose gel electrophoresis. Eligible DNA samples were broken into fragments of about 350 bp using Covaris ultrasonic crushing instrument and NEBNext Ultra DNA Library Prep Kit for Illumina Kit (NEB, USA) was used for sequencing library preparation. Library quality control was performed using Agilent 2100 Bioanalyzer (Agilent Technologies, Beijing, China) and the sequencing procedure was completed by Illumina NovaSeq PE150. Library construction, sequencing and comparative analysis between control and experimental groups were performed by Novogene Tech (Beijing) Co., Ltd.

RNA preparation and transcriptomic analyses

H. pylori NCTC 11637 strain grouping was the same as Genome DNA analysis and each group were run using three replicates. Total RNA was extracted with RNAprep Pure Cell/Bacteria Kit (DP430, TIANGEN, China) and quality control was assessed using agar gel electrophoresis, NanoPhotometer spectrophotometer and Agilent 2100 bioanalyzer for integrity and purity. Eligible RNA sample was treated with Ribo-Zero™ Magnetic Kit (Bacteria) (Epicentre, USA) to remove rRNA. The cDNA library was constructed according to the Strand-specific approach [19]. For the quality of the cDNA library, Qubit2.0 Fluorometer was used for preliminary quantification and then qRT-PCR was used for accurate quantification to ensure its effective concentration was above 2 nM. Library construction and sequencing were conducted by Novogene Tech (Beijing) Co., Ltd. Raw reads were filtered and mapped to the *H. pylori* NCTC 11637 genome using Bowtie2. Gene expression counts were quantified using HTSeq. Differentially expressed genes (DEGs) were analysed using DESeq2. Genes with absolute \log_2 fold changes > 0.5 and multiple p-value < 0.05 were considered as DEGs.

Gene expression measurement by qRT-PCR

Quantitative real-time polymerase chain reaction (qRT-PCR) assays were applied to detect the targeted gene expression. The same samples as in the RNA-sequencing transcriptomic analyses were used, including 3 controls incubated on blank medium and 3 incubated on medium contains 0.00125 mmol/ml zinc acetate. Based on transcriptomic analyses, 6 differentially expressed genes were selected for qRT-PCR validation. Gene-specific primers were designed using Primer Premier 5.0 and first strand cDNA was synthesized using HiFiScript cDNA Synthesis Kit (Cowin Bio, China). qRT-PCR reactions were performed in technical triplicates using an ABI StepOne Real-Time PCR System (Perkin-Elmer Applied Biosystems, Foster City, CA). Reaction component and process are shown in **Supplementary Table 6**. Gene expression and \log_2 fold changes were analyzed using the $2^{-\Delta\Delta CT}$ algorithm.

GO and KEGG pathway analyses

First we mapped genes to Entrez Gene symbols and then gene sets were annotated by GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) databases [20, 21]. GO enrichment analysis (cellular component (CC), molecular function (MF), and biological process (BP)) and KEGG pathway enrichment analysis of DEGs were performed using clusterProfiler R package (v3.4.4), while the

H. pylori 11637 reference strain annotated by Pfam (protein families database) was used as background, and Benjamini–Hochberg adjusted p-value < 0.05 was considered significantly enriched.

Construction of *ssrA* gene knocking-out strain

ssrA gene knock-out in *H. pylori* NCTC 11637 was constructed according to the published protocol [22] and summarised in **Supplementary Table 7**. The plasmid PILL570, which contains a kanamycin resistance gene, was kindly provided by Professor Yundong Sun from Shandong University, China. The recombinant plasmid for knocking out *oipA* gene (used as positive control in this study) was kindly provided by Professor Yong Xie, Nanchang University, China. Briefly, we amplified the upstream and downstream homologous arms of *ssrA* and then inserted them into PILL570 and transformed the reconstructed plasmid into the bacteria. The targeted genes (*ssrA* and *oipA*) would be replaced by the kanamycin resistance gene.

Knock-down of *ssrA* by siRNA

Levofloxacin-resistant *H. pylori* NCTC 11637 strain with a MIC of 4-6 µg/ml induced by gradient levofloxacin exposure *in vitro* was used for analysis. siRNA against *ssrA* was designed and synthesized by Saisofi Biotech (Jiangsu) Co., Ltd, China. - the sequence is shown in **Supplementary Table 8**. siRNA transfection was performed following the published protocols [23]. *H. pylori* strains were harvested from plates and washed three times with sterile 10% ice glycerol solution, 100 µl mixture was blended with 10 µg of siRNA and 10⁹ CFU bacteria was transferred to 0.1 cm electroporation cups (Biorad, USA). Transfection was performed by electroporation using 2500V for 5 ms. At 30 min, 1 h and 2 h after electrotransformation, bacterial RNA was extracted and reverse transcribed according to manufacturer's protocols (Vazyme, China). The qRT-PCR reaction components and processes are detailed in **Supplementary Table 9**. MICs of levofloxacin to *H. pylori* after *ssrA* was knocked down at different time points were tested using the E-strip method.

Results

Zinc acetate inhibits *H. pylori* growth

We cultured *H. pylori* (NCTC 11637) with zinc acetate for three days at 37°C. *H. pylori* growth was inhibited at increasing concentrations of zinc acetate which becomes apparent at 0.00125 mmol/ml, with complete inhibition observed at 0.0025 mmol/ml (p < 0.001, vs control). Similar effects were also observed with polaprezinc (**Fig. 1**). In addition to the standard strains, we also tested the resistance of various clinical *H. pylori* strains to zinc acetate (and polaprezinc) and found broadly comparable minimum inhibitory concentrations (MICs) across the various strains (**Supplementary Table S1**).

Zinc acetate increases *H. pylori* sensitivity to levofloxacin

Next, we investigated changes in *H. pylori* (NCTC 11637) sensitivity to levofloxacin, clarithromycin and tetracycline after culturing with zinc acetate or polaprezinc for three days. MICs of levofloxacin and clarithromycin decreased after *H. pylori* exposure to both zinc acetate and polaprezinc, although only the MIC of levofloxacin strictly remained below the resistance breakpoint [17] after exposure to zinc acetate (Table 1, Supplementary Figure S1). MICs of tetracycline remained unchanged in both conditions.

Table 1. Zinc Compounds affect the MIC ($\mu\text{g/ml}$) of Antibiotics to *H. pylori* NCTC 11637.

	Control	Polaprezinc	Zinc acetate
Levofloxacin	1-1.5	0.75-1	0.5-0.75
Clarithromycin	0.5-1	0.25-0.5	0.25-0.5
Tetracycline	0.5-1	0.5-1	0.5-1

Breakpoints of antibiotic sensitivity: Levofloxacin: MIC $\leq 1 \mu\text{g/ml}$; Clarithromycin: MIC $\leq 0.25 \mu\text{g/ml}$; Tetracycline: MIC $\leq 1 \mu\text{g/ml}$.

Transcriptomic changes in response to zinc acetate

To investigate the transcriptomic changes associated with decreased resistance of *H. pylori* to levofloxacin after exposure to zinc acetate, we used RNA-sequencing to assess gene expression changes after culturing *H. pylori* with zinc acetate for three days vs controls (n=3 each). The zinc acetate treated samples were separable from the control groups based on principal component analysis (PCA) using the transcriptomic profiles (Fig. 2a) and displayed distinct gene expression profiles (Fig. 2b). In total, we found 227 nominally significant ($p < 0.05$) differentially expressed genes (DEGs) between the treated and control groups, with 23 DEGs significant after adjustment for multiple correction (Fig. 2c, Supplementary Table S2). Additionally, we tested whether DEGs were enriched for any GO processes or KEGG pathway, and we did not find any significant enrichment after multiple correction (Supplementary Table S3, 4). Genome sequencing was also performed on *H. pylori* NCTC 11637 with zinc acetate treatment vs controls (n=3 each). Comparative genomics analyses including indels, single nucleotide polymorphisms, structural variations, synteny analyses, did not reveal changes as a result of zinc acetate exposure (Supplementary Table S5).

We independently tested 6 DEGs with the largest absolute fold expression changes (Table 2, Fig. 3a) that were nominally significant using qRT-PCR (n=3). We observed significant and consistent changes in expression for *ssrA* (DQL14_RS05110, also known as transfer- and messenger-RNA, tmRNA), where expression increased by 2.6-fold ($p = 0.02$, Figure 3b) after incubation with zinc acetate.

Table2. Six selected differentially expressed genes measured by qRT-PCR

Gene ID	Gene Name	Gene Description	ZA vs Con Log ₂ (Fold Change)	ZA vs Con p-value
DQL14_RS05110	<i>ssrA</i>	transfer-messenger RNA	0.874	3.81E-03
DQL14_RS05815	<i>hopJ</i>	Hop family outer membrane protein HopJ/HopK PF01856:Helicobacter outer membrane protein	-0.548	4.89E-02
DQL14_RS04055	-	hypothetical protein	-0.679	2.06E-02
DQL14_RS04690	-	hypothetical protein	0.652	1.03E-02
DQL14_RS03085	<i>rpmG</i>	50S ribosomal protein L33	2.116	4.11E-02
DQL14_RS08375	-	cag pathogenicity island protein	0.530	3.40E-04

Knockdown of *ssrA* restores *H. pylori* resistance to levofloxacin

After we replicated and validated increased expression of *ssrA* after zinc acetate treatment, we hypothesised whether *ssrA* expression is a potential causal mechanism driving the observed zinc acetate mediated *H. pylori* sensitivity to levofloxacin. First, we performed *ssrA* knock-out in *H. pylori* which led to complete inhibition of *H. pylori* growth, suggesting *ssrA* is essential for *H. pylori* growth (**Supplementary Figure S2**). Subsequently, we performed knock-down of *ssrA* in *H. pylori*, whereby siRNA *ssrA* knock-down reduced *ssrA* expression by 46%. The time course of knock-down results after *ssrA* siRNA treatment indicated that *ssrA* mRNA expression decreased the most after 1 hour (**Fig. 4a**). MICs of levofloxacin for the zinc acetate treated group after *ssrA* knock-down were restored to levels similar to controls, consistent with *ssrA* being a driver of zinc acetate associated levofloxacin sensitivity (**Fig. 4b**).

Discussion

Rising antibiotic resistance to *H. pylori* is fast becoming a widespread global health concern, driving the need for alternative and complementary treatment approaches. Here in this study, we demonstrated the role of zinc acetate in inhibiting *H. pylori* growth and increasing the sensitivity of *H. pylori* to levofloxacin -

a commonly used antibiotic in *H. pylori* treatment. In the process, we also reproduced previously observed effects of polaprezinc on *H. pylori* growth [16].

This is one of the first study to examine the transcriptomic perturbations associated with zinc acetate treatment, which showed distinct gene expression profiles compared to controls. Widespread transcriptomic perturbations were also previously seen after changes in environmental conditions such as temperature [24, 25]. This suggests significant transcriptomic changes occur in *H. pylori* in response to biophysical as well as chemical perturbations. Whilst we did not find evidence of enrichment for any specific pathways, we were able to test and validate the effects of the specific gene *ssrA* in detail via hypothesis driven functional follow-up.

Through siRNA knock-down of *ssrA*, we were able to restore *H. pylori* resistance to zinc acetate induced levofloxacin sensitivity, suggesting an important role of *ssrA* in driving these observed effects. *SsrA* codes for the highly conserved tmRNA, a specialized RNA with properties of both a tRNA and an mRNA. tmRNA is one of the key components of trans-translation - a ubiquitous bacterial mechanism that resolves ribosome stalling caused by non-stop mRNAs, which is diversely implicated in many processes such as responding to stress, pathogenesis, and differentiation [26]. Trans-translation is an essential function in bacteria [27], and play regulatory roles in organisms such as *H. pylori* [28], *Escherichia coli* [29], *Streptomyces coelicolor* [30], etc. We showed that complete *ssrA* knockout inhibits *H. pylori* growth completely, suggesting tmRNA system is essential for *H. pylori* growth – consistent with similar reports in other bacterial species [31]. Previous literature suggests that deletion of the tmRNA system reduces trans-translation and results in increased susceptibility to oxidative stress and antibiotics that inhibit protein synthesis and transcription [32]. However, we demonstrated that zinc acetate treatment led to increased *ssrA* expression and sensitivity to levofloxacin and knock-down of *ssrA* led restored resistance. Our results are consistent with *Streptococcus pneumoniae* containing *ssrA* deletion becoming more resistant to levofloxacin and other fluoroquinolones [32]. The exact mechanism by which this effect occurs in *H. pylori* remains to be elucidated.

Conclusion

In summary, our results suggest that zinc acetate reduces *H. pylori* growth and increases sensitivity to levofloxacin through upregulating tmRNA system along with other distinct transcriptomic changes and modulating the trans-translational system. Our findings support zinc acetate as a useful adjunct in fluoroquinolone-based antibiotic therapies against resistant *H. pylori*.

List Of Abbreviations

BP, biological process; CC, cellular component; CFU, colony forming units; DEGs, differentially expressed genes; E-test, Epsilometer test; FPKM, Fragments Per Kilobase of exon model per Million mapped fragments; GO, Gene Ontology; *H. pylori*, *Helicobacter pylori*; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; MIC, minimum inhibitory concentration; PBS, phosphate-buffered

saline; PCA, Principal component analysis; PCR, polymerase chain reaction; Pfam, protein families database; SDS, sodium dodecyl sulphate; tmRNA, transfer- and messenger-RNA.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The raw data associated with this paper will be made publicly available upon publication and upon request for peer view.

Competing interests

The authors declare that they have no competing interests.

Funding

NO funding.

Authors' contributions

H.T. carried out the *ssrA* gene knock-down and knock-out experiments and helped to draft the manuscript. F.M. performed the *H. pylori* growth and antibiotics susceptibility study and contributed to related data interpretation. J.F. and Y.H. carried out the bioinformatic analysis. Y.Z. and J.L. assisted with the antibiotics susceptibility testing and gene expression analysis. B.S. participated in data interpretation, analyzed the data and wrote the manuscript. G.W. designed and conceived of the study, revised the manuscript, and had primary responsibility for final content. All authors read and approved the final manuscript.

Acknowledgements

We acknowledge the technical assistance from Professor Jing Yuan (Capital Institute of Pediatrics, Beijing, China), Dr. Yu Tian (Laboratory of Translational Medicine, Medical Innovation Research Division of Chinese PLA General Hospital, Beijing, China) and Dr. Jingyi Wang Zhang (Medical School of Chinese PLA, Beijing, China).

Authors' information

¹ Department of Gastroenterology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China. ² Medical School of Chinese PLA, Beijing, China. ³ Department of Laboratory Medicine, Second Medical Center, Chinese PLA General Hospital, Beijing, China. ⁴ Institute of Geriatrics, National Clinical Research Center of Geriatrics Disease, Second Medical Center, Chinese PLA General Hospital, Beijing, China. ⁵ Department of Oncology, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. ⁶ MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.

References

1. Shafir, A., M. Shauly-Aharonov, L.H. Katz, O. Paltiel, Y. Pickman, and Z. Ackerman, The Association between Serum Vitamin D Levels and Helicobacter pylori Presence and Eradication. *Nutrients*, 2021;13:1:278.
2. Schulz, C., K. Schütte, and P. Malfertheiner, Helicobacter pylori and Other Gastric Microbiota in Gastrointestinal Pathologies. *Dig Dis*, 2016;34:3:210-6.
3. Plummer, M., S. Franceschi, J. Vignat, D. Forman, and C. de Martel, Global burden of gastric cancer attributable to Helicobacter pylori. *Int J Cancer*, 2015;136:2:487-90.
4. Mentis, A., P. Lehours, and F. Mégraud, Epidemiology and Diagnosis of Helicobacter pylori infection. *Helicobacter*, 2015;20 Suppl 1:1-7.
5. Eusebi, L.H., R.M. Zagari, and F. Bazzoli, Epidemiology of Helicobacter pylori infection. *Helicobacter*, 2014;19 Suppl 1:1-5.
6. Liou, J.M., P.Y. Chen, Y.T. Kuo, and M.S. Wu, Toward population specific and personalized treatment of Helicobacter pylori infection. *J Biomed Sci*, 2018;25:1:70.
7. Lee, Y.C., T.H. Chiang, C.K. Chou, Y.K. Tu, W.C. Liao, M.S. Wu, et al., Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. *Gastroenterology*, 2016;150:5:1113-1124.e5.
8. Kotilea, K., P. Bontems, and E. Touati, Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. *Adv Exp Med Biol*, 2019;1149:17-33.
9. Mahachai, V., R.K. Vilaichone, R. Pittayanon, J. Rojborwonwitaya, S. Leelakusolvong, M. Maneerattanaporn, et al., Helicobacter pylori management in ASEAN: The Bangkok consensus report. *J Gastroenterol Hepatol*, 2018;33:1:37-56.
10. Malfertheiner, P., F. Megraud, C.A. O'Morain, J.P. Gisbert, E.J. Kuipers, A.T. Axon, et al., Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut*, 2017;66:1:6-30.
11. Yang, J.C., C.W. Lu, and C.J. Lin, Treatment of Helicobacter pylori infection: current status and future concepts. *World J Gastroenterol*, 2014;20:18:5283-93.
12. Flores-Treviño, S., S. Mendoza-Olazarán, P. Bocanegra-Ibarias, H.J. Maldonado-Garza, and E. Garza-González, Helicobacter pylori drug resistance: therapy changes and challenges. *Expert Rev Gastroenterol Hepatol*, 2018;12:8:819-827.

13. Ayala, G., W.I. Escobedo-Hinojosa, C.F. de la Cruz-Herrera, and I. Romero, Exploring alternative treatments for *Helicobacter pylori* infection. *World J Gastroenterol*, 2014;20:6:1450-69.
14. Wang, Y., L. Hu, F. Xu, Q. Quan, Y.T. Lai, W. Xia, et al., Integrative approach for the analysis of the proteome-wide response to bismuth drugs in *Helicobacter pylori*. *Chem Sci*, 2017;8:6:4626-4633.
15. Tan, B., H.Q. Luo, H. Xu, N.H. Lv, R.H. Shi, H.S. Luo, et al., Polaprezinc combined with clarithromycin-based triple therapy for *Helicobacter pylori*-associated gastritis: A prospective, multicenter, randomized clinical trial. *PLoS One*, 2017;12:4:e0175625.
16. Kashimura, H., K. Suzuki, M. Hassan, K. Ikezawa, T. Sawahata, T. Watanabe, et al., Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxicillin and clarithromycin increases the cure rate of *Helicobacter pylori* infection. *Aliment Pharmacol Ther*, 1999;13:4:483-7.
17. European Committee on Antimicrobial Susceptibility Testing [ECUCAST]. Clinical Breakpoints – Bacteria (V 12.0), 2022. https://www.eucast.org/clinical_breakpoints/. Accessed 1 January 2022.
18. Lim, H.J., E.H. Lee, Y. Yoon, B. Chua, and A. Son, Portable lysis apparatus for rapid single-step DNA extraction of *Bacillus subtilis*. *J Appl Microbiol*, 2016;120:2:379-87.
19. Parkhomchuk, D., T. Borodina, V. Amstislavskiy, M. Banaru, L. Hallen, S. Krobitch, et al., Transcriptome analysis by strand-specific sequencing of complementary DNA. *Nucleic Acids Res*, 2009;37:18:e123.
20. Gene Ontology Consortium. The Gene Ontology resource: enriching a GOLD mine. *Nucleic Acids Res*, 2021;49:D1:D325-d334.
21. Kanehisa, M., Y. Sato, M. Kawashima, M. Furumichi, and M. Tanabe, KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res*, 2016;44:D1:D457-62.
22. Geng, X., W. Li, Z. Chen, S. Gao, W. Hong, X. Ge, et al., The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of *Helicobacter pylori* by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. *Antimicrob Agents Chemother*, 2017;61:5:e02011-16.
23. Yan, Y., W. Zhan, G. Zhao, J. Ma, and S. Cai, Use of SiRNA to investigate the role of CagA on *H. pylori* induced IL-8 production from gastric epithelial cells. *Hepatogastroenterology*, 2007;54:78:1868-73.
24. Gong, M., Y. Han, X. Wang, H. Tao, F. Meng, B. Hou, et al., Effect of Temperature on Metronidazole Resistance in *Helicobacter pylori*. *Frontiers in Microbiology*, 2021;12:1224:681911.
25. Donaldson, M.E., C.M. Davy, K.J. Vanderwolf, C.K.R. Willis, B.J. Saville, and C.J. Kyle, Growth medium and incubation temperature alter the *Pseudogymnoascus destructans* transcriptome: implications in identifying virulence factors. *Mycologia*, 2018;110:2:300-315.
26. Keiler, K.C., Biology of trans-translation. *Annu Rev Microbiol*, 2008;62:133-51.
27. Huter, P., C. Müller, S. Arenz, B. Beckert, and D.N. Wilson, Structural Basis for Ribosome Rescue in Bacteria. *Trends Biochem Sci*, 2017;42:8:669-680.
28. Thibonnier, M., J.M. Thiberge, and H. De Reuse, Trans-translation in *Helicobacter pylori*: essentiality of ribosome rescue and requirement of protein tagging for stress resistance and competence. *PLoS One*, 2008;3:11:e3810.

29. Li, J., L. Ji, W. Shi, J. Xie, and Y. Zhang, Trans-translation mediates tolerance to multiple antibiotics and stresses in *Escherichia coli*. *J Antimicrob Chemother*, 2013;68:11:2477-81.
30. Yang, C. and J.R. Glover, The SmpB-tmRNA tagging system plays important roles in *Streptomyces coelicolor* growth and development. *PLoS One*, 2009;4:2:e4459.
31. Kuo, H.K., R. Krasich, A.S. Bhagwat, and K.N. Kreuzer, Importance of the tmRNA system for cell survival when transcription is blocked by DNA-protein cross-links. *Mol Microbiol*, 2010;78:3:686-700.
32. Brito, L., J. Wilton, M.J. Ferrández, A. Gómez-Sanz, A.G. de la Campa, and M. Amblar, Absence of tmRNA Has a Protective Effect against Fluoroquinolones in *Streptococcus pneumoniae*. *Front Microbiol*, 2016;7:2164.

Figures




Figure 1

Zinc compounds inhibit the growth of *H. pylori* (NCTC 11637).




Figure 2

Differentially expressed genes (DEGs) identified by transcriptomic (RNA) sequencing. **A** Principal component analysis (PCA) analysis of tested samples. (Con, control group; ZA, zinc acetate treated group). **B** Hierarchical clustered heatmap of differentially expressed genes (n=227) between control and treated group. **C** Volcano plot exhibition of DEGs. The vertical axis represents the $-\log_{10}(\text{p-value})$, the horizontal axis displays the \log_2 fold change. Red points signify the up-regulated transcripts (n=121), green points stand for down-regulated transcripts (n=106). Vertical dashed lines indicate absolute \log_2 fold change = 0 and horizontal dashed lines indicate p-value = 0.05.






Figure 3

Validation of selected candidate genes using qRT-PCR. **A** Expression of 6 selected genes measured by RNA sequencing and assessed by Fragments Per Kilobase of exon model per Million mapped fragments (FPKM). Error bars indicate standard deviation. **B** Expression of 6 selected genes measured by qRT-PCR. $2^{-\Delta\Delta Ct}$ method was applied to evaluate gene expression differences. Error bars indicate standard deviation. Con, control group; ZA, zinc acetate treated group. (* $p \leq 0.05$).

A**B****Figure 4**

A The levels of *ssrA* expression after knock-down evaluated by qRT-PCR. $2^{-\Delta\Delta Ct}$ was used to evaluate the difference of gene expression (p-value by independent samples *t*-test). **B** The impact of *ssrA* knock-down on levofloxacin sensitivity. Left: *H. pylori* electroporation at 2500 V for 5 ms as control; the MIC of levofloxacin was 4.0 µg/ml. Right: *H. pylori* electroporation at 2500 V for 5 ms and transformed by siRNA to *ssrA* for 1 hour; the MIC of levofloxacin was 6.0-8.0 µg/ml.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.pdf](#)
- [Additionalfile2.xls](#)